Updated:
CUREXO
CUREXO, led by Jae-joon Lee, builds the CUVIS surgical-robotics platform with over 35,000 procedures performed globally from its Seoul base.
CUREXO
Founded in Seoul, CUREXO operates as a publicly traded commercial-stage medical-device company under CEO Jae-joon Lee. The firm designs, manufactures, and sells orthopedic surgical robots and rehabilitation robots, most notably the CUVIS-joint for knee and hip arthroplasty, the CUVIS-spine for spinal navigation, and the MorningWalk gait-rehabilitation system. Its origin lies in engineering-led product development rather than deployment of a family fortune. CUREXO generates revenue by selling capital equipment into hospitals and surgical centers, supplemented by per-procedure consumables. Asset classes are confined to its core product hardware, software, and implant-adjacent consumables. The device mix covers joint reconstruction, spinal fixation, and neurological rehabilitation stages. CUREXO maintains an open-platform strategy for CUVIS-joint, certifying compatibility with third-party implant systems, which has facilitated distribution tie-ups with implant-focused partners. Confirmed commercial partnerships include Italy’s Permedica (per the firm, 2026) and Droguepar S.A in Paraguay (per the firm, 2026), while KOL engagement programs run in Taiwan, Japan, Egypt, and India. Its geographic footprint covers Asia, Latin America, Europe, and North Africa. CUREXO holds a public listing on South Korea’s KOSDAQ market (ticker 060280) and reports its financials publicly under KRX disclosure rules. The firm established an India subsidiary in 2025 and has concurrently deepened its Latin American channel with a Paraguay supply contract and Mexico’s COFEPRIS approval for CUVIS-spine (per the firm, May 2026). Team size, valuation, and total deployment are not disclosed; as a commercial manufacturing entity, its scale is measured in units placed and regulatory clearances rather than assets under management. No family-office or adjacent wealth-management vehicles are publicly associated with the firm. What distinguishes CUREXO among surgical-robotics peers is its deliberate emerging-market pathway — pursuing regulatory wins and distributor relationships in countries such as Mexico, Paraguay, Egypt, and Morocco while larger Western competitors focus on the US and mature European reimbursement corridors. This serialized per-country approval model, paired with an open-platform implant strategy, creates a hardware footprint that can expand with local implant partners rather than requiring a proprietary implant ecosystem.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
Asia
Country
South Korea
City
Seoul
Corporate office
Seoul, South Korea
Additional offices
India
Principals
Jae-joon Lee
CEO
Sector focus
Frequently asked questions
Who runs investment decisions at CUREXO?
CUREXO is a publicly traded operating company, not an asset manager or family office. Capital-allocation and strategic decisions are made by CEO Jae-joon Lee and the board of directors, with reporting obligations to KOSDAQ shareholders. The firm does not manage third-party capital or run an investment portfolio.
Is CUREXO structured as a single-family office or a commercial enterprise?
It is a commercial medical-robotics manufacturer listed on South Korea’s KOSDAQ exchange (ticker 060280). There is no family-office structure, no pool of family-origin capital, and no multi-family-office service offering. The firm generates revenue from the sale and support of surgical and rehabilitation robotic systems.
How does CUREXO source its commercial pipeline?
CUREXO sources hospital and distributor accounts through a mix of direct in-country subsidiaries — including an India subsidiary established in 2025 — and exclusive distribution agreements. Recent distributor wins include Permedica for Italy and North Africa, Droguepar S.A for Paraguay, and Artimedica for Mexico, complementing KOL-led clinical demonstration programs in Taiwan, Japan, and Egypt.
What investment stages or asset classes does CUREXO target?
As a commercial manufacturer, CUREXO does not target investment stages. Its capital deployment occurs through internal R&D, regulatory filings (FDA, CE MDR, COFEPRIS, and other local clearances), and direct sales-channel expansion. The hardware portfolio spans three device families: CUVIS-joint, CUVIS-spine, and MorningWalk.
Which geographies does CUREXO actively sell into?
CUREXO sells into Asia (South Korea, Japan, India, Taiwan), Latin America (Brazil, Paraguay, and recently approved entry into Mexico), Europe (Italy, with CE MDR certification enabling broader EU distribution), and North Africa (Morocco and Egypt via Permedica and local partners). The US market is accessible via its FDA clearance.
Does CUREXO participate in fund commitments or co-investments alongside external GPs?
No. CUREXO’s capital goes into product development, manufacturing, and geographic commercialization. The firm does not allocate to fund commitments, direct private-company investments, or co-investment vehicles of any kind.
How does the open-platform implant strategy affect CUREXO’s competitive position?
CUREXO designed CUVIS-joint to work with multiple implant manufacturers rather than locking hospitals into a proprietary implant system. This strategy allows CUREXO to partner with established implant companies in different regions — Permedica in Italy, for example — and accelerates hospital adoption where surgeons want to maintain their existing implant preferences while adding robotic-assisted precision.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: